title: Effect of methamphetamine neurotoxicity on learning-induced Arc mRNA expression in identified striatal efferent neurons.
abstract: Methamphetamine abuse results in lasting, partial depletions of striatal dopamine and cognitive dysfunction. However, the effect of partial dopamine depletions on the expression of an effector immediate early gene, Arc (activity regulated, cytoskeletal-associated protein), known to be involved in synaptic modifications underlying learning and memory, has heretofore not been examined. Male Sprague-Dawley rats were pretreated with a neurotoxic regimen of methamphetamine or saline. Seven weeks later, rats were trained in a motor-response task on a T-maze for five days, and then underwent reversal training on day five. Rats were sacrificed 5 min after reaching criterion on the reversal task, and the brains were removed and processed using double-label fluorescent in situ hybridization for Arc and preproenkephalin (PPE) mRNA expression in the dorsomedial striatum. Rats pretreated with methamphetamine had an average (+/-SEM) 54.4+/-7.9% loss of dopamine in dorsomedial striatum. Interestingly, there was no difference in reversal trials to criterion in methamphetamine- vs. saline-pretreated rats. However, the expression of Arc mRNA in dorsomedial striatum was attenuated in methamphetamine-pretreated animals, particularly in PPE-negative neurons. Furthermore, the correlation between Arc mRNA expression in dorsomedial striatum and learning was abolished in methamphetamine-pretreated animals. These data suggest that methamphetamine-induced partial monoamine loss is associated with disrupted induction of the effector immediate early gene Arc during a behavioral task, particularly in PPE-negative (presumed striatonigral) neurons, as well as with disruption of the relation between Arc mRNA expression in dorsomedial striatum and reversal learning.
authors.affiliation: Departments of Pharmacology and Toxicology, Psychology, and Program in Neuroscience, University of Utah, Salt Lake City, UT 84112, USA.
authors.forename: David P
authors.initials: DP
authors.lastname: Daberkow
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Riedy
authors.forename: Raymond P
authors.initials: RP
authors.lastname: Kesner
authors.forename: Kristen A
authors.initials: KA
authors.lastname: Keefe
mesh_terms: D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003598:Cytoskeletal Proteins / Q000187:drug effects / Q000235:genetics*; D004298:Dopamine / Q000378:metabolism; D004745:Enkephalins / Q000235:genetics / Q000378:metabolism; D017781:Genes, Immediate-Early / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D008694:Methamphetamine / Q000633:toxicity*; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000235:genetics*; D009476:Neurons, Efferent / Q000187:drug effects* / Q000378:metabolism*; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012193:Reversal Learning / Q000187:drug effects
chemical_list: D003598:Cytoskeletal Proteins; D004745:Enkephalins; D009419:Nerve Tissue Proteins; D011498:Protein Precursors; D012333:RNA, Messenger; C092069:activity regulated cytoskeletal-associated protein; D008694:Methamphetamine; C033660:preproenkephalin; D004298:Dopamine